Opioid substitution treatment reduces substance use equivalently in patients with and without posttraumatic stress disorder.
OBJECTIVE
The purpose of this study was to determine whether opioid-dependent patients with diagnosed posttraumatic stress disorder (PTSD) have poorer long-term outcomes in opioid substitution treatment than do patients without PTSD.


METHODS
This prospective observational study examined outcomes of 255 opioid-dependent patients (men = 248) entering opioid substitution treatment at eight clinics in the Veterans Health Administration (VHA). Subjects were interviewed at treatment entry, 6 months, and 1 year about substance use and related problems, health status, treatment satisfaction, and non-VHA health care utilization. Medical records were reviewed to obtain toxicology results, health care utilization data, and diagnoses. Medical record review identified a diagnosis of PTSD in 71 (28%) patients. Substance-use and mental-health outcomes and health care utilization in the first year following treatment entry were compared between patients with and without a diagnosis of PTSD.


RESULTS
Patients with and without PTSD had similar treatment responses. Although patients with PTSD had longer histories of drug use at intake, at 1-year follow-up they showed reductions in heroin, cocaine, and alcohol use, comparable to patients without the disorder. PTSD patients received higher doses of opiate medication, attended more psychosocial treatment sessions for substance-use disorder, and had better treatment retention. Psychiatric symptoms for patients with PTSD were more severe at intake and showed little improvement throughout treatment.


CONCLUSIONS
Opioid substitution therapy is as effective at reducing substance use in PTSD patients as it is in patients without the disorder, but additional services are needed for treatment of psychological problems that are largely unchanged by treatment for addiction.
Center for Health Care Evaluation, Veterans Affairs Palo Alto Health Care System, California, USA. Jodie.Trafton@med.va.gov
Jodie A
JA
Trafton
Jared
J
Minkel
Keith
K
Humphreys
D000328:Adult; D000368:Aged; D000437:Alcoholism / Q000453:epidemiology / Q000523:psychology / Q000534:rehabilitation; D019970:Cocaine-Related Disorders / Q000453:epidemiology / Q000523:psychology; D003130:Combat Disorders / Q000453:epidemiology / Q000523:psychology* / Q000534:rehabilitation*; D015897:Comorbidity; D005260:Female; D005500:Follow-Up Studies; D006305:Health Status Indicators; D006556:Heroin Dependence / Q000453:epidemiology / Q000523:psychology / Q000534:rehabilitation; D006801:Humans; D013287:Illicit Drugs; D008297:Male; D002189:Marijuana Abuse / Q000453:epidemiology / Q000523:psychology / Q000534:rehabilitation; D008691:Methadone / Q000008:administration & dosage*; D008875:Middle Aged; D009294:Narcotics / Q000008:administration & dosage*; D009293:Opioid-Related Disorders / Q000453:epidemiology / Q000523:psychology / Q000534:rehabilitation*; D011379:Prognosis; D012307:Risk Factors; D015813:Substance Abuse Detection; D016896:Treatment Outcome; D014728:Veterans / Q000523:psychology*
D013287:Illicit Drugs; D009294:Narcotics; D008691:Methadone